文献速递其他结缔组织病

系统性自身免疫性肌病:灭活SARS-CoV-2疫苗的前瞻性4期对照试验

Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

这项前瞻性对照研究纳入53例系统性自身免疫性肌病(SAMs)患者和106例非免疫抑制对照,均接种两剂Sinovac-CoronaVac疫苗。结果显示SAMs患者抗SARS-CoV-2 S1/S2 IgG血清转化率、GMT和中和抗体阳性率均显著低于对照,但中和活性中位数两组相当;疫苗相关不良事件轻微且频率相似。免疫抑制剂使用与中和抗体阳性率降低相关。

要点

  • SAMs患者接种两剂Sinovac-CoronaVac后血清转化率64.9%,显著低于对照的91.1%。
  • SAMs患者中和抗体阳性率51.4%,显著低于对照的77.2%。
  • 免疫抑制剂使用在NAb+患者中比例低于NAb-患者(73.7% vs 100%)。

核心结论

  • Sinovac-CoronaVac在SAMs患者中安全,短期免疫原性中等但低于对照。
  • 免疫抑制与中和抗体阳性率降低相关。

研究设计与样本

  • 前瞻性对照4期试验,纳入53例SAMs患者和106例非免疫抑制对照,均接种两剂Sinovac-CoronaVac(间隔28天)。
  • 免疫原性分析纳入37例SAMs患者和79例基线未感染对照。

主要发现

  • D69时SAMs患者血清转化率64.9% vs 对照91.1%(P<0.001)。
  • D69时SAMs患者GMT为7.9(95%CI 4.7-13.2)UA/ml vs 对照24.7(95%CI 30.0-30.5)UA/ml(P<0.001)。
  • D69时SAMs患者中和抗体阳性率51.4% vs 对照77.2%(P<0.001)。
  • 中和活性中位数两组相当:57.2%(IQR 43.4-83.4) vs 63.0%(IQR 40.3-80.7),P=0.808。
  • 免疫抑制剂在NAb+患者中使用比例低于NAb-患者(73.7% vs 100%,P=0.046)。

关键数值与推荐

  • SAMs类型、疾病状态、其他药物或合并症未影响免疫原性。
  • 疫苗相关不良事件轻微,患者与对照频率相似(P>0.05)。

临床怎么用

  • SAMs患者接种灭活SARS-CoV-2疫苗安全,但免疫原性低于对照。
  • 使用免疫抑制剂的患者中和抗体阳性率可能降低。

局限性

  • 免疫原性分析排除了基线IgG或NAb阳性及协议期间RT-PCR确诊COVID-19者。
  • 样本量较小,随访为短期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in systemic autoimmune myopathies (SAMs) and the possible influence of baseline disease parameters, comorbidities and therapy on immune response. METHODS: This prospective controlled study included 53 patients with SAMs and 106 non-immunocompromised control group (CTRL). All participants received two doses of the Sinovac-CoronaVac vaccine (28-day interval). Immunogenicity was assessed by anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC), anti-S1/S2 IgG geometric mean titre (GMT), factor increase GMT (FI-GMT), neutralizing antibodies (NAb) positivity, and median neutralizing activity after each vaccine dose (D0 and D28) and six weeks after the second dose (D69). Participants with pre-vaccination positive IgG serology and/or NAb and those with RT-PCR confirmed COVID-19 during the protocol were excluded from immunogenicity analysis. RESULTS: Patients and CTRL had comparable sex (P>0.99) and age (P=0.90). Immunogenicity of 37 patients and 79 CTRL-naïve participants revealed at D69, a moderate but significantly lower SC (64.9% vs 91.1%, P<0.001), GMT [7.9 (95%CI 4.7-13.2) vs 24.7 (95%CI 30.0-30.5) UA/ml, P<0.001] and frequency of NAb (51.4% vs 77.2%, P<0.001) in SAMs compared with CTRL. Median neutralizing activity was comparable in both groups [57.2% (interquartile range (IQR) 43.4-83.4) vs 63.0% (IQR 40.3-80.7), P=0.808]. Immunosuppressives were less frequently used among NAb+ patients vs NAb- patients (73.7% vs 100%, P=0.046). Type of SAMs, disease status, other drugs or comorbidities did not influence immunogenicity. Vaccine-related adverse events were mild with similar frequencies in patients and CTRL (P>0.05). CONCLUSION: Sinovac-CoronaVac is safe and has a moderate short-term immunogenicity in SAMs, but reduced compared with CTRL. We further identified that immunosuppression is associated with diminished NAb positivity. TRIAL REGISTRATION: COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS (CoronavRheum), http://clinicaltrials.gov/ct2/show/NCT04754698.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Shinjo SK, de Souza FHC, Borges IBP, et al. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology (Oxford). 2022. PMID: 34664616. doi:10.1093/rheumatology/keab773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。